Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

At least $65 million slated for 14 of 35 Alzheimer's disease research centers is in limbo, with funding expected to run out ...

Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.

Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...

The South San Francisco biotech announced that eIF2B agonist DNL343 was unable to slow disease progression or increase survival compared to placebo at 24 weeks in the study, conducted at Sean M ...

On March 5, 2025, Denali Therapeutics ( DNLI) Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment ...

Vandana Singh Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well ...